Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acufal-Plus is a multi-ingredient nutraceutical combination supplement developed by Acure Pharma, an Indian pharmaceutical company. Formulated as an oral tablet, it contains a synergistic blend of active vitamins and nutrients, including L-methylfolate (the active form of folate), methylcobalamin (vitamin B12), pyridoxal 5-phosphate (the active form of vitamin B6), vitamin D3 (cholecalciferol), and docosahexaenoic acid (DHA), along with biotin and choline. The supplement is designed to support the one-carbon/folate metabolic pathways, activate the vitamin D receptor, and provide essential omega-3 fatty acids. It is primarily indicated for nutritional supplementation and the treatment or prevention of folate, vitamin B12, and vitamin D deficiencies, thereby supporting metabolic and neurological health. The product is currently approved and marketed in India.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acufal-Plus.